In murine BC models, the inhibition of CSF1/CSF1R signaling through either CSF1 monoclonal antibodies or the CSF1R tyrosine kinase inhibitor PLX3397 results in the depletion of TAMs and significantly postpones tumor recurrence following radiotherapy (74). This evidence concerns the gene CSF1 and breast cancer.